Daniel Su1, Lambros Stamatakis, Eric A Singer, Ramaprasad Srinivasan. 1. aUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland bSection of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Abstract
PURPOSE OF REVIEW: Renal cell carcinoma (RCC) continues to be the subject of vigorous clinical and translational investigation. Advances in systemic targeted therapies, new molecular pathways and immunotherapy approaches will be discussed. RECENT FINDINGS: Agents targeting the vascular endothelial growth factor (VEGF) and/or the mammalian target of rapamycin (mTOR) pathways continue to be the mainstay for treating metastatic RCC (mRCC). Although enhanced target specificity has improved the toxicity profile associated with newer VEGF-pathway antagonists, durable complete responses remain the exception. Identification of novel pathways/agents, as well as the optimal sequencing and combination of existing targeted agents, remain areas of active study. In addition, emerging data from early clinical trials have reinvigorated interest in immunomodulatory agents. SUMMARY: The therapeutic armamentarium available to genitourinary oncologists continues to grow, but much work remains to be done to fully realize the potential of pathway-specific targeted strategies and immune-based approaches for mRCC.
PURPOSE OF REVIEW: Renal cell carcinoma (RCC) continues to be the subject of vigorous clinical and translational investigation. Advances in systemic targeted therapies, new molecular pathways and immunotherapy approaches will be discussed. RECENT FINDINGS: Agents targeting the vascular endothelial growth factor (VEGF) and/or the mammalian target of rapamycin (mTOR) pathways continue to be the mainstay for treating metastatic RCC (mRCC). Although enhanced target specificity has improved the toxicity profile associated with newer VEGF-pathway antagonists, durable complete responses remain the exception. Identification of novel pathways/agents, as well as the optimal sequencing and combination of existing targeted agents, remain areas of active study. In addition, emerging data from early clinical trials have reinvigorated interest in immunomodulatory agents. SUMMARY: The therapeutic armamentarium available to genitourinary oncologists continues to grow, but much work remains to be done to fully realize the potential of pathway-specific targeted strategies and immune-based approaches for mRCC.
Authors: Robert J Motzer; Dmitry Nosov; Timothy Eisen; Igor Bondarenko; Vladimir Lesovoy; Oleg Lipatov; Piotr Tomczak; Oleksiy Lyulko; Anna Alyasova; Mihai Harza; Mikhail Kogan; Boris Y Alekseev; Cora N Sternberg; Cezary Szczylik; David Cella; Cristina Ivanescu; Andrew Krivoshik; Andrew Strahs; Brooke Esteves; Anna Berkenblit; Thomas E Hutson Journal: J Clin Oncol Date: 2013-09-09 Impact factor: 44.544
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Dmitry A Nosov; Brooke Esteves; Oleg N Lipatov; Alexei A Lyulko; A A Anischenko; Raju T Chacko; Dinesh C Doval; Andrew Strahs; William J Slichenmyer; Pankaj Bhargava Journal: J Clin Oncol Date: 2012-04-09 Impact factor: 44.544
Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245
Authors: David F McDermott; Meredith M Regan; Joseph I Clark; Lawrence E Flaherty; Geoffery R Weiss; Theodore F Logan; John M Kirkwood; Michael S Gordon; Jeffrey A Sosman; Marc S Ernstoff; Christopher P G Tretter; Walter J Urba; John W Smith; Kim A Margolin; James W Mier; Jared A Gollob; Janice P Dutcher; Michael B Atkins Journal: J Clin Oncol Date: 2005-01-01 Impact factor: 44.544
Authors: A Ari Hakimi; Ying-Bei Chen; James Wren; Mithat Gonen; Omar Abdel-Wahab; Adriana Heguy; Han Liu; Shugaku Takeda; Satish K Tickoo; Victor E Reuter; Martin H Voss; Robert J Motzer; Jonathan A Coleman; Emily H Cheng; Paul Russo; James J Hsieh Journal: Eur Urol Date: 2012-09-27 Impact factor: 20.096
Authors: Aikseng Ooi; Karl Dykema; Asif Ansari; David Petillo; John Snider; Richard Kahnoski; John Anema; David Craig; John Carpten; Bin-Tean Teh; Kyle A Furge Journal: Cancer Res Date: 2013-01-30 Impact factor: 12.701
Authors: Jessica D Sun; Dharmendra Ahluwalia; Qian Liu; Wenwu Li; Yan Wang; Fanying Meng; Deepthi Bhupathi; Mark D Matteucci; Charles P Hart Journal: Am J Cancer Res Date: 2015-06-15 Impact factor: 6.166
Authors: Bray Denard; Andrea Pavia-Jimenez; Weina Chen; Noelle S Williams; Harris Naina; Robert Collins; James Brugarolas; Jin Ye Journal: PLoS One Date: 2015-06-25 Impact factor: 3.240
Authors: Ki Cheong Park; Jun Hyeok Heo; Jeong Yong Jeon; Hye Ji Choi; A Ra Jo; Seung Won Kim; Ho Jeong Kwon; Sung Joon Hong; Kyung Seok Han Journal: BMC Cancer Date: 2015-01-23 Impact factor: 4.430